Concept Life Sciences Further Strengthens Its Team With The Appointment Of Dr Andrew Clifton As Head Of Bioassay Development And Screening Technologies
Dr Andrew Clifton joins Concept Life Sciences as Head of Bioassay Development and Screening Technologies. Concept Life Sciences offers tailored preclinical services including integrated drug discovery programs providing its international client base with world class integrated services.
Dr Clifton will be responsible for providing assay development and screening capabilities to support preclinical drug discovery projects from hit finding through to candidate selection.
Andrew has over eighteen years’ experience in both large pharma and biotech through his roles at AstraZeneca and Redx Pharma. Andrew’s expertise is in biochemistry and pharmacology with experience across major drug target classes including a wide variety of enzymes and GPCRs. He has extensive experience of assay development and screening applied to hit finding, hit to lead and lead optimisation and has contributed to the delivery of multiple clinical candidates. His therapy area experience includes oncology, inflammation/fibrosis and respiratory. Prior to commencing his pharmaceutical career, Andrew completed his doctoral training with Professor Sir Philip Cohen at the University of Dundee MRC Protein Phosphorylation Unit.
Commenting on his appointment Andrew stated: “I am delighted to be joining Concept Life Sciences at this exciting time in its development. Concept is generally recognised as a leading global provider of preclinical drug discovery services, and I look forward to building our assay development and screening capability to support integrated drug discovery projects. I also look forward to supporting the groups many integrated discovery and development partners, from virtual biotechs to big pharma.”
Commenting on Dr Clifton’s appointment, Dr Chris Doe, Head of Biology at Concept Life Sciences said: “I am delighted to welcome Dr Andrew Clifton to the team. Andrew’s expert knowledge and track record in this field will further strengthen our existing team and underpin our services as a leading UK CRO in Integrated Discovery & Development Services.”
Dr Clifton will be responsible for providing assay development and screening capabilities to support preclinical drug discovery projects from hit finding through to candidate selection.
Andrew has over eighteen years’ experience in both large pharma and biotech through his roles at AstraZeneca and Redx Pharma. Andrew’s expertise is in biochemistry and pharmacology with experience across major drug target classes including a wide variety of enzymes and GPCRs. He has extensive experience of assay development and screening applied to hit finding, hit to lead and lead optimisation and has contributed to the delivery of multiple clinical candidates. His therapy area experience includes oncology, inflammation/fibrosis and respiratory. Prior to commencing his pharmaceutical career, Andrew completed his doctoral training with Professor Sir Philip Cohen at the University of Dundee MRC Protein Phosphorylation Unit.
Commenting on his appointment Andrew stated: “I am delighted to be joining Concept Life Sciences at this exciting time in its development. Concept is generally recognised as a leading global provider of preclinical drug discovery services, and I look forward to building our assay development and screening capability to support integrated drug discovery projects. I also look forward to supporting the groups many integrated discovery and development partners, from virtual biotechs to big pharma.”
Commenting on Dr Clifton’s appointment, Dr Chris Doe, Head of Biology at Concept Life Sciences said: “I am delighted to welcome Dr Andrew Clifton to the team. Andrew’s expert knowledge and track record in this field will further strengthen our existing team and underpin our services as a leading UK CRO in Integrated Discovery & Development Services.”